Please assess the completion status of the following clinical trial:

Trial Title: Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. willing to give informed consent~2. man or woman of any race and ≥12 years of age~3. able to understand and willing to comply with study procedures, restrictions and requirements~4. Clinical findings consistent with Acanthamoeba keratitis~5. Confocal microscopy findings consistent with Acanthamoeba keratitis~6. The following previous treatments for Acanthamoeba keratitis are eligible: antibiotics, antiviral and antifungal drugs, antiinflammatory drugs~7. Females of childbearing potential will be included if they are either sexually inactive or using one highly effective contraceptive~8. Females of childbearing potential agree to remain sexually inactive or to keep the same birth control method for at least 28 days following the last study drug dose~9. A female of non-childbearing potential must have undergone one sterilization procedures at least 6 months prior to the first study drug dose~10. A non-vasectomized male subject agrees to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study drug and the female partner agrees to comply with inclusion 7 or 8. For a vasectomized male who has had his vasectomy 6 months or more prior to study start, it is required that they use a condom during sexual intercourse. A male who has been vasectomized less than 6 months prior to study start must follow the same restrictions as a non-vasectomized male.~11. If male, they must agree not to donate sperm from the first study drug dose until 90 days after dosing~Exclusion Criteria:~1. Subject with documented history and/or clinical signs of concomitant presence of an ocular infection caused by viruses (herpes simplex virus \[HSV\]) or fungi.~2. Subject treated with drugs having effects on Acanthamoeba cysts prior to study entry, including biguanides (PHMB, chlorhexidine) and diamidines (propamidine, hexamidine).~3. Subjects requiring systemic immunosuppression for Acanthamoeba associated scleritis.~4. Subjects requiring urgent surgical intervention for advanced Acanthamoeba keratitis in either eye (e.g., for advanced corneal thinning/melting etc.).~5. Subject with known or suspected allergy to biguanides, diamidines or intolerance to any other ingredient of the investigational treatments.~6. Subject affected by immunodeficiency diseases or taking systemic immunosuppressive therapy.~7. Subject with a major systemic disease or other illness that would, in the opinion of the investigator, compromise subject's safety or interfere with the collection or interpretation of study results.~8. If female, pregnancy, planned pregnancy, or breast-feeding~9. Subject is participating in another interventional clinical study with an experimental or unapproved/unlicensed therapy or has participated in another interventional clinical study within 4 weeks prior to this study.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PHMB 0.08% plus placebo (Type: EXPERIMENTAL): polihexanide (PHMB) 0.08% and placebo were administered in the affected eye until clinical resolution for a maximum of 12 months
- PHMB 0.02% plus propamidine 0.1% (Type: ACTIVE_COMPARATOR): polihexanide (PHMB) 0.02% and propamidine 0.1% were administered in the affected eye until clinical resolution for a maximum of 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete